IPD
data caveat$29M13mo
ImpediMed Limited
Medical Devices · Oncology
Medical device company commercialising the SOZO bioimpedance spectroscopy platform, FDA-cleared for lymphedema detection and heart failure fluid monitoring, with 90%+ reimbursement coverage across 27 US states.
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$18.9M
Dec 2025 4C
Runway
13moADEQUATE
Based on Dec 2025 4C
Market Cap
$29M
Burn Rate
$4.3M/qtr
Dec 2025 4C
Shares Outstanding
2.0B
Pipeline Assets
3
Latest Insights(2)
25 Feb 2026Half YearFY26 Half Year Financial Results
Cash$18.8M·Burn$8.5M/q·OCF$-8.5M
Half YearAppendix 4D and Interim Financial Report
Cash$18.8M·Burn$8.5M/q·OCF$-8.5M
3M Price
IPD.ASX$0.014-57.6% 3M
Low $0.013High $0.033
Pipeline Assets (3)
SOZO / L-DexLymphedema (breast cancer-related)
ApprovedSOZO / HF-DexHeart failure fluid monitoring
ApprovedSOZO / BodyCompBody composition analysis
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-04-17 · 4-day lag
Short position
0.63%
arrow_drop_up+0.05% over 2 reports
Shares short
12.9M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
Competitive Landscape
2 competitor trialsPhase 2+ · Non-ASX
Lymphedema (Breast Cancer-Related)2 active trials
1 Ph2/31 Ph2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (3)
US reimbursement expansion — ongoing
UpcomingConfirmedarrow_upwardHigh31 Dec 2026
Profitability / cash flow breakeven milestone
UpcomingExpectedarrow_upwardHigh31 Dec 2026
AstraZeneca CKD/HF Phase IIb trial data
UpcomingSpeculativeremoveMed30 June 2027
| Event | Type | Confidence | Impact | Date | Status |
|---|
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Clinical Trials(4)
1 activeClinicalTrials.gov ↗
NAActive Not RecruitingEnrollment stale · 2945d
20-30 mmHg compression sleeve and gauntletManual Lymphatic Drainage
Subclinical Lymphedema Treatment Study
Breast Cancer-related Subclinical Lymphedema
RandomizedOpen Label18 Years+
Primary endpoint L-dex scores